Polymorphisms in the methylenetetrahydrofolate reductase gene are determinant for vascular complications after liver transplantation

European Journal of Clinical Nutrition

Volumn 62, Issue 3, 2008, Pages 430-435

  Akoglu, B ^a   Kindl, P ^a   Weber, N ^a   Trojan, J ^a   Caspary, W F ^a   Faust, D ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; CYCLOSPORIN A; HOMOCYSTEINE; MYCOPHENOLIC ACID; RAPAMYCIN; RESTRICTION ENDONUCLEASE; TACROLIMUS; VALINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BILE DUCT DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; GRAFT RECIPIENT; HEART DISEASE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; PERIPHERAL VASCULAR DISEASE; POLYMERASE CHAIN REACTION; PROBABILITY; STROKE; UNIVERSITY HOSPITAL; VASCULAR DISEASE; VEIN THROMBOSIS; WILD TYPE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; LIVER TRANSPLANTATION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 40549098155     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602699     Document Type: Article

References (32)

1. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM et al. (1997). Ten years of liver transplantation: An evolving understanding of late graft loss. Transplantation 64, 1801-1807.
2. Akoglu B, Milovic V, Caspary WF, Faust D (2004). Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. Eur J Nutr 43, 93-99.
3. Akoglu B, Wondra K, Caspary WF, Faust D (2006). Determinants of fasting serum homocysteine in liver transplant recipients. Exp Clin Transplant 4, 462-466.
4. Bosy-Westphal A, Ruschmeyer M, Czech N, Oehler G, Hinrichsen H, Plauth M et al. (2003). Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 77, 1269-1277.
5. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ (2002). Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 75, 908-913.
6. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al. (2003). Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349, 847-858.
7. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M (1999). Homocysteine in cerebral macroangiography and microangiopathy. Lancet 353, 1586-1587.
8. Fernandez-Miranda C, Gomez P, Diaz-Rubio P, Estenoz J, Carillo JL, Andres A et al. (2000). Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: Effect of treatment with folic acid. Clin Transplant 14, 110-114.
9. Fernandez-Miranda C, Sanz M, de La Calle A, Loinaz C, Gomez P, Diaz-Rubio P et al. (2001). Determinants of increased plasma homocysteine in 221 stable liver transplant patients. Clin Chem 47, 2037-2040.
10. Fodinger M, Wolfl G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Horl WH et al. (1999). Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Kidney Int 55, 1072-1080.
11. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG (2002). Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2, 308-313.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. (1995). A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113.
13. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE et al. (1996). The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Qjm 89, 571-577.
14. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J (2002). Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73, 901-906.
15. Kang SS, Wong PW, Bock HG, Horwitz A, Grix A (1991). Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 48, 546-551.
16. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG (2002). MTHFR 677C → T polymorphism and risk of coronary heart disease: A meta-analysis. Jama 288, 2023-2031.
17. Miller JW, Nadeau MR, Smith J, Smith D, Selhub J (1994). Folate-deficiency-induced homocysteinaemia in rats: Disruption of S-adenosylmethionine's co-ordinate regulation of homocysteine metabolism. Biochem J 298, 415-419.
18. Minniti G, Piana A, Armani U, Cerone R (1998). Determination of plasma and serum homocysteine by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 828, 401-405.
19. Moench C, Moench K, Lohse AW, Thies J, Otto G (2003). Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl 9, 285-289.
20. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD et al. (2004). Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 77, 93-99.
21. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR et al. (2001). Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 7, 811-815.
22. Quiroga I, Morris-Stiff G, Baboo R, Darby CR, Lord RH, Jurewicz WA (2001). Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. Transplant Proc 33, 1209-1210.
23. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ (2001). Late mortality after orthotopic liver transplantation. Am J Surg 181, 475-479.
24. Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, Wilson PW et al. (2003). Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study Cohort. J Nutr 133, 3416-3421.
25. Schachinger V, Britten MB, Elsner M, Walter DH, Scharrer I, Zeiher AM (1999). A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 100, 1502-1508.
26. Shihab FS (1996). Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin Nephrol 16, 536-547.
27. Stanger O, Weger M, Renner W, Konetschny R (2001). Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 39, 725-733.
28. Sudan DLVA, Lynch J, Fox IJ, Shaw B, Langnas AN (1999). Causes of late mortality in survivors of liver transplantation. Abstract 67 S564.
29. Ueland PM, Refsum H, Beresford SA, Vollset SE (2000). The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72 324-332.
30. van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, Trijbels FJ, Eskes TK, Mariman EC et al. (1996). Decreased methylene tetrahydrofolate reductase activity due to the 677C → T mutation in families with spina bifida offspring. J Mol Med 74, 691-694.
31. Wald DS, Law M, Morris JK (2002). Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 325 1202.
32. Wu LL, Wu JT (2002). Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 322, 21-28.